US 12,478,428 B2
Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum
Ilan Ben Oren, Modiin (IL); Irit Yaniv, Ramat Gan (IL); Tamir Wolf, Tel Aviv (IL); and Avia Herschkovitz, Rehovot (IL)
Assigned to DIGMA MEDICAL LTD., Petah Tikva (IL)
Filed by DIGMA MEDICAL LTD., Petah Tikva (IL)
Filed on Jun. 20, 2023, as Appl. No. 18/211,997.
Application 18/211,997 is a continuation of application No. 16/707,125, filed on Dec. 9, 2019, abandoned.
Application 16/707,125 is a continuation of application No. 15/303,080, granted, now 10,537,387, issued on Jan. 21, 2020, previously published as PCT/IL2015/050410, filed on Apr. 16, 2015.
Claims priority of provisional application 62/030,641, filed on Jul. 30, 2014.
Claims priority of provisional application 61/980,618, filed on Apr. 17, 2014.
Prior Publication US 2023/0346476 A1, Nov. 2, 2023
Int. Cl. A61B 18/02 (2006.01); A61B 5/00 (2006.01); A61B 6/00 (2006.01); A61B 18/00 (2006.01); A61B 18/22 (2006.01); A61N 5/06 (2006.01); A61B 1/012 (2006.01); A61B 5/01 (2006.01); A61B 5/026 (2006.01); A61B 5/055 (2006.01); A61B 5/107 (2006.01); A61B 8/00 (2006.01); A61B 8/08 (2006.01); A61B 8/12 (2006.01); A61B 18/20 (2006.01); A61B 18/26 (2006.01); A61B 90/00 (2016.01); A61N 7/00 (2006.01)
CPC A61B 18/22 (2013.01) [A61B 5/4255 (2013.01); A61B 6/00 (2013.01); A61B 18/02 (2013.01); A61N 5/0603 (2013.01); A61N 5/062 (2013.01); A61N 5/0625 (2013.01); A61B 1/012 (2013.01); A61B 5/0066 (2013.01); A61B 5/0086 (2013.01); A61B 5/015 (2013.01); A61B 5/026 (2013.01); A61B 5/055 (2013.01); A61B 5/1076 (2013.01); A61B 8/085 (2013.01); A61B 8/12 (2013.01); A61B 8/445 (2013.01); A61B 2018/00029 (2013.01); A61B 2018/00273 (2013.01); A61B 2018/00285 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00494 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00589 (2013.01); A61B 2018/00601 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00714 (2013.01); A61B 2018/00744 (2013.01); A61B 2018/00779 (2013.01); A61B 2018/00785 (2013.01); A61B 2018/00809 (2013.01); A61B 2018/00904 (2013.01); A61B 2018/00982 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/20355 (2017.05); A61B 2018/20359 (2017.05); A61B 2018/2261 (2013.01); A61B 2018/2266 (2013.01); A61B 2018/2277 (2013.01); A61B 2018/2283 (2013.01); A61B 18/26 (2013.01); A61B 2090/061 (2016.02); A61B 2090/3735 (2016.02); A61B 2090/378 (2016.02); A61B 2218/001 (2013.01); A61B 2505/05 (2013.01); A61N 2005/063 (2013.01); A61N 2005/0659 (2013.01); A61N 7/00 (2013.01); A61N 2007/003 (2013.01); A61N 2007/0043 (2013.01); A61N 2007/0052 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for reducing neural activity in a duodenum of a subject, the method comprising:
introducing a catheter comprising an electrical energy transducer into the duodenum of the subject;
transmitting electrical energy to the duodenum, wherein the electrical energy is configured to be absorbed by different layers of the duodenum in a target area;
lowering a temperature of the target area utilizing a cooling mechanism, thereby causing selective ablation of sensory nerves located in a submucosal layer of the target area to at least partially reduce the neural activity within the submucosal layer having absorbed the electrical energy, while maintaining functional activity of a mucosal layer within the treated target area and/or functional activity of areas surrounding the treated target area.